BCR and chronic myelogenous leukemia, BCR-ABL1 positive: As a result, the dephosphorylation and degradation activity of SPOA on BCR-ABL synergistically inhibited proliferation and promoted apoptosis in imatinib sensitive and resistant CML cells.